MedTrace Logo

A Pilot Study of Lithium in Progressive Multiple Sclerosis

NCT01259388 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-09-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.

Conditions

Interventions

DRUG

Lithium Carbonate

Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • John R Rinker, MD · Birmingham VA Medical Center, Birmingham, AL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2015-08-31
Completion
2015-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01259388 on ClinicalTrials.gov